Acelyrin, Inc.

The proposed all-stock merger of troubled Acelyrin with Alumis, first announced on 6 February, will go forward, Acelyrin said 4 March, stating it will decline an unsolicited acquisition offer from Tan

Alumis stands to bulk up its financial position as well as its portfolio of drugs to treat immune-mediated diseases through its merger with Acelyrin. But while analysts saw the deal as a positive from

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Potential competitors to Amgen’s Tepezza (teprotumumab), the only approved drug therapy for thyroid eye disease (TED), keep lining up as privately held Sling Therapeutics unveiled positive Phase IIb/I